Cellectis Wyss Institute, Cellectis to Collaborate on Cell Line Genome Recoding Project The partners' first project will involve using Cellectis' TALEN gene editing technology to create virus-resistant human cells. Cellectis Plant Genomics Subsidiary Calyxt Prices $56M IPO Calyxt increased the number of shares it intends to float, but slashed its offering price in half from the middle of a previously disclosed range. Non-CRISPR Genome-Editing Technologies Find Niche in Biotech Applications Premium CRISPR is the paradigm now in research applications, but companies with IP rights to TALENs and zinc finger nucleases are pushing forward with those technologies. Calyxt Licenses Plant Gene-Targeting IP from U of Minnesota The technology is for gene targeting using endocunleases and homologous recombination, and is the second licensing deal between the parties since April. Gene Editing Drives Development of Cancer T-Cell Therapies Premium Cellectis, Janssen, and others plunge into cell therapy with the help of several genome-editing technologies, including TALENs and CRISPR/Cas9. Apr 16, 2015 Cellectis Plant Sciences Inks CRISPR/Cas9 Licensing Deal with U of Minnesota Apr 9, 2015 Cellectis Launches US Subsidiary Mar 25, 2015 Cellectis Prices American Depositary Shares, Expects to Go Public Today Dec 19, 2014 Cellectis, Two Blades Ink TALEN Technology Cross-licensing Deal Jul 29, 2014 Cellectis Sells Human Stem Cell Subsidiary to Takara Bio Jun 5, 2014 Thermo Fisher, Cellectis Enter Licensing Pact Covering TAL Nucleases Feb 4, 2014 Cellectis Sublicenses Technology to Genoway for Rodent Model-based Research Jan 31, 2014 Precision BioSciences, Cellectis Settle Genome Engineering IP Dispute Sep 27, 2013 Cellectis' Operating Revenues Slide 8 Percent in First Half of 2013 May 6, 2013 Precision Bio Wins Patent Infringement Lawsuit Filed by Cellectis Mar 7, 2013 Cellectis, Stemgent Partner on Genome Engineering, mRNA Reprogramming Nov 9, 2012 In Brief This Week: Illumina; Thermo Fisher Scientific; Accler8; Precision BioSciences, Cellectis; BG Medicine; More Oct 25, 2012 Cellectis Licenses TAL Technology from Iowa State Apr 27, 2012 In Brief This Week: Life Technologies; LifeCodexx; Luminex; Quanterix; Precision BioSciences, Cellectis; Ocimum Biosolutions; BGI, Aspera; IDBS, ChemAxon, Thomson Reuters; Genome Designs, SciDM Group Mar 30, 2012 In Brief This Week: Ariosa Diagnostics; Abbott; Quidel; Precision BioSciences, Cellectis; Vermillion; Rosetta Genomics; BGI; NeoGenomics; Warnex; ClearBridge BioMedics Mar 16, 2012 In Brief This Week: AB Sciex; Enzo Biochem; Sigma-Aldrich; Precision BioSciences, Cellectis; Quidel; Galapagos, AstraZeneca; Cartagenia Mar 6, 2012 Precision BioSciences Files Fifth Patent Lawsuit Against Cellectis Feb 28, 2012 Precision BioSciences Files Fourth Patent Lawsuit Against Cellectis Feb 21, 2012 Precision BioSciences Files More Lawsuits Against Cellectis Alleging Patent Infringement Feb 13, 2012 Cellectis Redeeming Bonds for $66M Load More Breaking News New Products Posted to GenomeWeb: Qiagen, Thermo Fisher, Bionano Genomics, BillionToOne, More People in the News at Illumina Ventures, Element Biosciences, Epigenomics, Exagen, More Genomic Approaches Boost Rare Disease Diagnoses in Middle Eastern Patient Population GeneDx to Raise $150M in Public and Direct Stock Offerings In Brief This Week: T2 Biosystems, Novacyt, OpGen, Dante Genomics, Nautilus Biotechnology, More The Scan Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups. Genome-Wide Analysis Sheds Light on Genetics of ADHD A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder. MicroRNA Cotargeting Linked to Lupus A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus. Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.